关键微小RNA作为尼洛替尼治疗慢性髓性白血病缓解的预测生物标志物:ENESTxtnd临床试验子分析
该研究分析ENESTxtnd IIIb期临床试验加拿大子分析中58例慢性髓性白血病患者尼洛替尼治疗前后CD34+细胞的差异表达微小RNA,结合体外集落形成细胞检测,利用Cox比例风险分析和机器学习构建多变量微小RNA组合,发现miR-145与miR-708可预测初治患者尼洛替尼缓解,miR-150与miR-185为治疗后1个月和3个月的重要分类标志物。
要点
- miR-145与miR-708组合可有效预测初治慢性髓性白血病患者的尼洛替尼缓解。
- miR-150与miR-185是尼洛替尼治疗后1个月和3个月的重要分类标志物。
- 将尼洛替尼集落形成细胞检测结果纳入预测组合可增强预测性能。
核心结论
- miR-145与miR-708组合是初治患者尼洛替尼缓解的有效预测因子,miR-150与miR-185是治疗后1个月和3个月的重要分类标志物。
- 将尼洛替尼集落形成细胞检测输出纳入预测组合可增强预测性能。
- 该新型预测模型可能被开发为临床使用的预后工具。
研究设计与样本
- 研究为ENESTxtnd IIIb期临床试验的加拿大子分析。
- 纳入58例慢性髓性白血病患者,分析尼洛替尼治疗前后CD34+细胞的差异表达微小RNA。
- 微小RNA表达与体外集落形成细胞检测中CD34+细胞对尼洛替尼的敏感性相关联。
- 采用Cox比例风险分析和机器学习算法构建多变量微小RNA组合。
主要发现
- miR-145与miR-708组合是初治患者尼洛替尼缓解的有效预测因子。
- miR-150与miR-185是尼洛替尼治疗后1个月和3个月的重要分类标志物。
- 将尼洛替尼集落形成细胞检测输出纳入预测组合可增强预测性能。
临床怎么用
- 作者认为该新型预测模型可能被开发为临床使用的预后工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the effectiveness of tyrosine kinase inhibitors (TKIs) against chronic myeloid leukemia (CML), they are not usually curative as some patients develop drug-resistance or are at risk of disease relapse when treatment is discontinued. Studies have demonstrated that primitive CML cells display unique miRNA profiles in response to TKI treatment. However, the utility of miRNAs in predicting treatment response is not yet conclusive. Here, we analyzed differentially expressed miRNAs in CD34+ CML cells pre- and post-nilotinib (NL) therapy from 58 patients enrolled in the Canadian sub-analysis of the ENESTxtnd phase IIIb clinical trial which correlated with sensitivity of CD34+ cells to NL treatment in in vitro colony-forming cell (CFC) assays. We performed Cox Proportional Hazard (CoxPH) analysis and applied machine learning algorithms to generate multivariate miRNA panels which can predict NL response at treatment-naïve or post-treatment time points. We demonstrated that a combination of miR-145 and miR-708 are effective predictors of NL response in treatment-naïve patients whereas miR-150 and miR-185 were significant classifiers at 1-month and 3-month post-NL therapy. Interestingly, incorporation of NL-CFC output in these panels enhanced predictive performance. Thus, this novel predictive model may be developed into a prognostic tool for use in the clinic.
引用
- Yen R, Grasedieck S, Wu A, et al. Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial. Leukemia. 2022. PMID: 35999259. doi:10.1038/s41375-022-01680-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。